Corporate, Press release

New Addition to the Management Board

23. avril 2024

The new Technical Operations business unit of the Freiburg-based family company will be headed up by Dr. Andreas Rascher in the future.

Since 15 April 2024, Dr. Andreas Rascher has been responsible for the business unit Technical Operations at Dr. Falk Pharma GmbH in Freiburg-Hochdorf. His arrival means that the existing management board has grown, consisting previously of Philipp Argast, Managing Director Finance & Administration, Dr. Kai Pinkernell, Managing Director Science & Innovation, and Torben Zachmann, Managing Director Commercial.

Dr. Andreas Rascher has a doctorate in pharmacy and has been working in the pharmaceutical industry in Germany and abroad for over 20 years. His main area is the field of drug manufacture, in particular tablets and biopharmaceuticals. Before joining Dr. Falk Pharma, he was responsible for the production plant of a large, multinational pharmaceutical company in which dosage forms were manufactured using biotechnology. “I am looking forward to my new roles at Falk, an innovative and growing family-owned business that not only carries out research and development in Germany, but also produces here. My passion lies in production and in the complete, sometimes also complex, manufacturing processes of a wide range of different drugs and dosage forms – and I like doing this together with all the people who are involved in the process, in particular with the experts working on the machines.”

With the creation of a fourth business unit, Technical Operations, the expert in digestive and metabolic medicine has underlined the huge importance of the production of its products for indications in the areas of gastroenterology and hepatology. All medicinal products from Dr. Falk Pharma are manufactured solely in Europe, mostly in Germany. The drugs are often characterised by innovative galenic formulations, thanks to which the active substance is released in the body at exactly the point where it is designed to act. Well over half of the company's products are manufactured by development and manufacturing company Losan Pharma GmbH (a wholly-owned subsidiary) after joint development. The remainder is produced by other contract manufacturers from outside the group.

The production of high-quality medicines in different dosage forms for more than 70 different countries all around the world in cooperation with multiple different partners is a complex task and a real challenge for pharmaceutical companies, particularly in the modern world. This is why the two company shareholders from the Falk family, Carola Falk and Dr. Martin Falk, are so delighted that they “have been able to bring Dr. Andreas Rascher on board as the Managing Director for the business unit Technical Operations. He brings many years of experience in production and plant management and will be supporting us in the future not only in the fields of Quality and Supply Chain, but also in terms of our strategic cooperation with Losan Pharma.”

New Management Board at Dr. Falk Pharma GmbH: Dr. Kai Pinkernell, Managing Director Science & Innovation and Philipp Argast, Managing Director Finance & Administration (both standing), Torben Zachmann, Managing Director Commercial and Dr. Andreas Rascher, Managing Director Technical Operations (both sitting)

Digital photographs in print-ready resolution are available to illustrate this press release. They may only be used for editorial purposes. Use is free of charge when credit is given as “Photo: Dr. Falk Pharma GmbH”. Graphic editing – except for cropping out the main motif – is prohibited.

Press release & contactPDF